Selvita S.A. [WSE: SLV] announced today completion of a strategic transaction in which it has acquired 100% of shares in PozLab. The closing of the transaction comes shortly after the announcement of the transaction on March 27, 2024.
PozLab is a contract development and manufacturing organization (“CDMO”) offering expert drug product development services and small pilot plant capabilities, including analytical, formulation, and process development competencies, followed by microbiological testing. Moreover, PozLab holds a GMP license for the manufacture of medical and investigational products. The Company currently employs over 80 dedicated subject matter experts and is located in state-of-the-art R&D facilities in Poznan, Poland, which offer approx. 1700 m2 of research space.
The acquisition of PozLab substantially expands Selvita’s capabilities in the rapidly growing pharmaceutical research sector. Selvita extends its value chain beyond preclinical research, enabling, in particular, the provision of small molecule drug manufacturing services for early-stage clinical trials. This strategic move enriches Selvita’s portfolio with additional valuable competencies, positioning the company as a comprehensive solution provider in the pharmaceutical industry.
We are very excited that as of today, PozLab is formally part of the Selvita Group. A lot of effort has gone into the completion of this transaction, and we are certain that it’s a very important milestone for the development of Selvita’s CDMO offer.
I would like to extend a very warm welcome to our new colleagues in Poznan. It’s wonderful to have them on board and I am looking forward to all the synergies this new relationship will bring – said Bogusław Sieczkowski, President of the Management Board of Selvita.
